Compare RSSS & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSSS | CYPH |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 73.4M |
| IPO Year | 2008 | N/A |
| Metric | RSSS | CYPH |
|---|---|---|
| Price | $2.29 | $1.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 99.4K | ★ 4.3M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.77 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $28,793,922.00 | N/A |
| Revenue This Year | $1.81 | N/A |
| Revenue Next Year | $5.73 | N/A |
| P/E Ratio | $32.60 | ★ N/A |
| Revenue Growth | ★ 2.77 | N/A |
| 52 Week Low | $2.00 | $0.50 |
| 52 Week High | $4.12 | $3.70 |
| Indicator | RSSS | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 51.23 |
| Support Level | $2.16 | $0.88 |
| Resistance Level | $2.66 | $1.30 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 38.67 | 27.35 |
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.